Suven Pharmaceuticals Ltd. - Research Center
543064 SUVENPHAR Group (A) BSE data
Add to watchlist
| Results |
Half yearly
|
| Statement | |
| More |
Half yearly results in brief
(Rs crore)
| Sep ' 23 | Sep ' 22 | Mar ' 22 | Sep ' 21 | Sep ' 20 | |
|---|---|---|---|---|---|
| Sales | 568.65 | 617.20 | 755.43 | 564.79 | 475.62 |
| Operating profit | 267.24 | 261.38 | 343.60 | 236.39 | 210.60 |
| Interest | 1.65 | 1.72 | 2.93 | 3.30 | 6.47 |
| Gross profit | 289.85 | 280.95 | 484.34 | 277.21 | 210.23 |
| EPS (Rs) | 7.82 | 7.58 | 14.20 | 7.72 | 11.51 |
Half yearly
results in details
| Sep ' 23 | Sep ' 22 | Mar ' 22 | Sep ' 21 | Sep ' 20 | |
|---|---|---|---|---|---|
| Other income | 24.26 | 21.29 | 143.67 | 44.12 | 6.10 |
| Stock adjustment | 30.47 | -15.31 | -18.98 | -41.37 | 1.19 |
| Raw material | 124.57 | 196.63 | 248.76 | 210.70 | 143.18 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 52.78 | 50.68 | 56.13 | 44.35 | 38.37 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | 4.31 | 4.33 | - | 6.89 |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 93.58 | 119.51 | 121.59 | 114.72 | 75.38 |
| Provisions made | - | - | - | - | - |
| Depreciation | 21.63 | 21.30 | 20.93 | 18.17 | 14.56 |
| Taxation | 69.20 | 66.67 | 101.95 | 62.40 | 49.10 |
| Net profit / loss | 199.02 | 192.97 | 361.46 | 196.64 | 146.56 |
| Extra ordinary item | - | - | - | - | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 25.46 | 25.46 | 25.46 | 25.46 | 12.73 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 47.00 | 42.35 | 45.48 | 41.85 | 44.28 |
| GPM (%) | 48.89 | 44.00 | 53.87 | 45.53 | 43.64 |
| NPM (%) | 33.57 | 30.22 | 40.20 | 32.29 | 30.42 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis